Table 2.
Patient's treatment characteristics and outcomes.
| Patient | Episode of CMV when CMVIG was used | Recurrent vs refractory CMV infection | CMV Viral load (log) | Days from HSCT/CMV infection to CMVIG | Antiviral tratment (with CMVIG) | Response/Days to response | Subsequent reactivation/days to subsequent reactivation | CMV-specific cytotoxic T-lymphocytes | Post-HSCT follow-up (months) | Current status/Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | Refractory | 4.00 | 50/31 | Cidofovir | No | Not applicable | No | 3 | Died/acute hemorrhage |
| 2 | 2 | Recurrent | 3.99 | 73/59 | Cidofovir | Yes/45 | No | No | 7 | Died/leukoencephalopathy |
| 3 | 1 | Refractory | 3.38 | 9/0 | Foscarnet | No | No | No | 27 | Alive |
| 4 | 3 | Recurrent | 4.55 | 126/100 | Ganciclovir | Yes/16 | Yes/30 | No | 30 | Alive |
| 5 | 2 | Recurrent | 3.45 | 270/245 | Foscarnet | Yes/28 | Yes/26 | No | 38 | Alive |
| 6 | 1 | Refractory | 4.75 | 48/28 | Valganciclovir | No | Not applicable | Yes | 13 | Died/CMV pneumonia |
| 7 | 2 | Recurrent | 4.60 | 231/202 | Cidofovir | Yes/15 | No | No | 24 | Alive |
| 8 | 1 | Refractory | 5.09 | 55/30 | Ganciclovir + Foscarnet | Yes/22 | No | No | 12 | Alive |
| 9 | 3 | Recurrent | 3.24 | 125/99 | Cidofovir | Yes/35 | Yes/15 | No | 7 | Died/invasive fungal infection |
| 10 | 4 | Recurrent | 3.80 | 217/187 | Foscarnet | Yes/28 | Yes/60 | No | 18 | Alive |
| 11 | 1 | Refractory | 5.12 | 73/23 | Ganciclovir | Yes/19 | No | No | 12 | Alive |
| 12 | 3 | Recurrent | 3.43 | 155/134 | Ganciclovir | No | Not applicable | Yes | 14 | Alive |
| 13 | 1 | Refractory | 2.76 | 62/61 | Foscarnet | No | Not applicable | Yes | 8 | Alive |
| 14 | 3 | Recurrent | 3.64 | 179/161 | Ganciclovir | Yes/27 | No | No | 16 | Alive |
| 15 | 1 | Refractory | 3.36 | 63/38 | Foscarnet | Yes/50 | No | No | 8 | Alive |